NASDAQ: ALGS

Aligos Therapeutics, Inc.

Healthcare | Biotechnology

$4.28

Market Cap$30M

Volume9.8K

EPS (FY2025)$-2.45

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a $30M biotechnology company trading at $4.28. Figures from SEC EDGAR and market feeds; updated 2026-10-11 00:41 UTC.

What Aligos Therapeutics, Inc. does

Aligos is a clinical-stage biotechnology company developing treatments for liver diseases and viral infections, including chronic hepatitis B, metabolic dysfunction-associated steatohepatitis, obesity, and coronavirus infections. The company's lead candidate, pevifoscorvir sodium, is a capsid assembly modulator in Phase 2 testing for chronic HBV infection that has demonstrated enhanced viral suppression in clinical trials. A second program, ALG-055009, is a thyroid hormone receptor agonist in Phase 2a development for metabolic liver disease and obesity.

Summarized from Aligos Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price	$4.28
Market cap	$30M
Volume	9.8K shares
Valuation	8-K 2026-06-26
EPS (FY2025)	$-2.45
Price/book	0.56×

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-06-29

Most recent filed transactions — June 2026:

2026-06-29DirectorAward5,860—
2026-06-29DirectorAward5,860—
2026-06-29DirectorAward5,860—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Deep Track Capital, LP444,110$2.56M0.0%
Alyeska Investment Group, L.P.412,000$2.38M0.0%
READYSTATE ASSET MANAGEMENT LP203,113$1.99M+48.5%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-02-04Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-02-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2021-06-24Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Aligos Therapeutics GAAP EPS of -$0.14
Seeking Alpha Markets2026-08-06
Fewer than five qualifying stories — full tape in the platform →

Questions this page answers

What does Aligos Therapeutics, Inc. do?

What is ALGS's valuation?

ALGS trades at $4.28, as of 2026-10-11.

When did ALGS last file with the SEC?

Aligos Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-10-11 00:41 UTC. This page is also available as JSON at /api/data?ticker=ALGS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ALGS and 5,000+ tickers.

Create a free account — keep ALGS

For your agent

GET /api/data?ticker=ALGS

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt